09:29 AM EDT, 05/13/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) said Monday that two-year data from an analysis of a late-stage trial showed "significant and sustained improvements in renal function" in people with chronic hypoparathyroidism treated with TransCon PTH.

The results were presented during this year's European Congress of Endocrinology, the company said.

Ascendis said the late-stage study enrolled 82 adults with chronic hypoparathyroidism, which is caused by inadequate levels of PTH, the main regulator of calcium and phosphate balance in the body.